NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CymaBay Therapeutics, Inc. (NASDAQ: CBAY) on behalf of CymaBay stockholders. Our investigation concerns whether CymaBay has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On January 29, 2020, CymaBay announced in a letter from its President and CEO, that it had been “working to assess all potential ways to maximize value for our shareholders, including liquidation, sale, merger, asset acquisitions, and/or continuing development of our internal programs.”
On this news, CymaBay stock dropped $0.21 per share, or over 11%, to close at $1.65 on January 30, 2020.
If you purchased or otherwise acquired CymaBay shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato or Marion Passmore by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.